ctDNA and the Enduring Role of Value-Based Models: Lalan Wilfong, MD
Published by
AJMC
on
During the 2025 Community Oncology Conference hosted by the Community Oncology Alliance (COA), Lalan Wilfong, MD, moderated a session on circulating tumor DNA (ctDNA), an emerging tool that holds promise for cancer diagnosis, treatment monitoring, and early detection of recurrence. He also shared his perspective on the lasting role of value-based care in oncology, despite policy uncertainty, in an interview with The American Journal of Managed Care®.
Wilfong, a medical oncologist at Texas Oncology, serves as the senior vice president of value-based care at Thyme Care and is chair of the COA Payer Reform Committee.